Absolute Antibody is proud to be supporting the researchers who are working to better understand, diagnose, treat and prevent COVID-19. Our staff is working hard to provide antibody engineering and manufacturing services, as well as coronavirus-related reagents, to help in the worldwide fight against the coronavirus pandemic.
Below we look at some examples of the coronavirus work going on within our company. If we can help advance your coronavirus-related research, or keep other important projects moving forward during this unprecedented time, please contact us.
Our reagents catalog includes 33 different coronavirus antibodies, including the CR3022 clone, which has been shown to detect SARS-CoV-2, the virus that causes COVID-19. All are recombinantly produced and available in multiple engineered formats designed to open up new experimental possibilities for in vitro and in vivo use. For example, the CR3022 clone is available in human, mouse and rabbit formats, in IgM, IgA and various IgG isotypes, as well as Fab and Fab2 fragments.
These antibodies are helping further research into the biology of COVID-19, as well as working their way into diagnostic kits that are rapidly being developed to test for COVID-19 positive patients.
We specialize in antibody sequencing, engineering and recombinant manufacturing, and we are leveraging our expertise and production capacity to support several coronavirus-related projects to develop potential therapeutic antibodies, including the production of gram quantities of human antibodies sequenced from convalescent patients. While we can’t go into detail on these collaborations yet, we are working hard to support both industry and academic endeavors to treat coronavirus infections. You can learn about our antibody services here.
Our Sister Company
In 2018, Absolute Antibody merged with Kerafast Inc., a Boston-based company with a mission to facilitate access to unique reagents developed by academic laboratories. Coronavirus-related reagents in their catalog include several antibodies and a Delta-G-VSV pseudotyping system that enables studies of viral entry and vaccine effectiveness at just BSL-2 containment.
In addition, their program provides a way for researchers to quickly share any of their own coronavirus reagents with the global scientific community. Learn about making reagents available here.
Our Coronavirus Response
We look forward to continuing our support of the researchers fighting the coronavirus pandemic. We typically help scientists develop treatments that may or may not become drugs in the next five to twenty years (with some notable exceptions, of course, such as during the 2015-2016 Zika virus outbreak). Now, with coronavirus spreading quickly throughout the world, we are all operating on a rapid timeline that is rare in biomedical science. You can read our latest company updates on the coronavirus situation here.
Our entire company wishes that you and your families remain healthy and safe during this very difficult time. Please don’t hesitate to contact us to discuss your research project or with any questions or concerns.
Antibody Engineering & Therapeutics Europe – Booth #26
7-9th June 2022